People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AnBio Therapeutics Ltd. | — | Biotechnology | Series C | $60.9M | $1.6B | 2021 |
| GD Culture Group Ltd | — | Other | Series B | $37.3M | $22.7M | 2021 |
Wei Xu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Wei Xu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Yun Zhang | 1 | 3 |
| Yi Li | 1 | 3 |
| Lei Zhang | 1 | 3 |
| Ting Jia | 1 | 2 |
| Xiao Jian Wang | 1 | 1 |
| Zihao Zhao | 1 | 1 |
| Shuaiheng Zhang | 1 | 1 |
| Mingyue Cai | 1 | 1 |
| Yi Zhong | 1 | 1 |
| Shuang Zhang | 1 | 1 |
| Yimin Jin | 1 | 1 |
| Weidong Feng | 1 | 1 |
| Jianing Yu | 1 | 1 |
| Fei Gan | 1 | 1 |
| Qihai Wang | 1 | 1 |
| Jin Wang | 1 | 1 |
| Yajing Li | 1 | 1 |
| Bibo Lin | 1 | 1 |
| Lihua Zheng | 1 | 1 |
| Junyuan Wang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.